(Q34726350)

English

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities? (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1

object named as

Bo Ahrén

1 reference

Europe PubMed Central

4 August 2017

author name string

James Edward Foley

2

1 reference

Europe PubMed Central

4 August 2017

Sylvie Dejager

3

1 reference

Europe PubMed Central

4 August 2017

Mouna Akacha

4

1 reference

Europe PubMed Central

4 August 2017

Qing Shao

5

1 reference

Europe PubMed Central

4 August 2017

Guenter Heimann

6

1 reference

Europe PubMed Central

4 August 2017

Markus Dworak

7

1 reference

Europe PubMed Central

4 August 2017

Anja Schweizer

8

1 reference

Europe PubMed Central

4 August 2017

publication date

18 September 2014

1 reference

Europe PubMed Central

4 August 2017

Diabetes Therapy

1 reference

Europe PubMed Central

4 August 2017

5

1 reference

Europe PubMed Central

4 August 2017

2

1 reference

Europe PubMed Central

4 August 2017

459-469

1 reference

Europe PubMed Central

4 August 2017

copyright license

Creative Commons Attribution 4.0 International

18 September 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s13300-014-0082-y

0 references

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Oral Antidiabetic Agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in mediating glucagon release in normal humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal n

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Pathogenesis of impaired glucose tolerance and type II diabetes mellitus--current status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4269641

7 July 2018

Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Cost of hypoglycemia in patients with Type 2 diabetes in Sweden

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0082-Y

21 January 2018

Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25230877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25230877

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13300-014-0082-Y

1 reference

Europe PubMed Central

4 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34726350&oldid=1981153528"